Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
CUPRIOR (JACE Pharma Pty Ltd)
Product name
CUPRIOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 (255 working days)
Active ingredients
trientine tetrahydrochloride
Registration type
NCE/NBE
Indication
CUPRIOR (film-coated tablet) is indicated for the treatment of Wilson's disease in adults, adolescents and children≥5 years intolerant to D-penicillamine therapy.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.